LXRX Q3 2022 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39,000+69.6% YoY

Gross Profit

$39,000100.0% margin

Operating Income

-$23M-59217.9% margin

Net Income

-$23M-59966.7% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+11.4%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$192M

Total Liabilities

$48M

Stockholders' Equity

$144M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39,000	$23,000	+69.6%
Gross Profit	$39,000	$23,000	+69.6%
Operating Income	-$23M	-$23M	-0.6%
Net Income	-$23M	-$23M	-1.1%